SOCRA CCRP Study Protocols 3

Question 1

What is the purpose of specifying stopping rules in a clinical trial protocol?

Accepted Answer

To define predetermined criteria for early termination of the trial based on safety concerns, futility, or overwhelming efficacy

Answer

Stopping rules are predetermined statistical or clinical criteria specified in the protocol that trigger early termination of the trial if subjects face unacceptable risk, the treatment shows overwhelming benefit, or the trial is unlikely to demonstrate a meaningful effect.

Question 2

What information must the protocol provide about concomitant medications?

Accepted Answer

A list of permitted, prohibited, and restricted concomitant medications along with guidelines for managing drug interactions

Answer

The protocol must specify which concomitant medications and treatments are permitted, restricted, or prohibited during the trial, along with instructions for managing subjects who require prohibited medications.

Question 3

What is the difference between a primary endpoint and a secondary endpoint in a clinical trial protocol?

Accepted Answer

The primary endpoint is the main outcome measure on which the sample size is based, while secondary endpoints provide supportive evidence

Answer

The primary endpoint is the principal outcome measure that the trial is powered to evaluate and forms the basis for the sample size calculation, while secondary endpoints provide additional supportive or exploratory evidence about the treatment's effects.

Question 4

How should the protocol address subject withdrawal and discontinuation?

Accepted Answer

The protocol must specify criteria for subject withdrawal, procedures for discontinuation, and the type and timing of data to be collected from withdrawn subjects

Answer

The protocol must describe the criteria that would lead to subject withdrawal, the procedures for orderly discontinuation, and what follow-up data should be collected from withdrawn subjects, including safety follow-up requirements.

Question 5

What is a protocol-specified visit window and why is it important?

Accepted Answer

A defined acceptable time range around each scheduled study visit that allows for scheduling flexibility while maintaining data quality

Answer

Visit windows define the acceptable range of days around each scheduled study visit (e.g., Day 28 ± 3 days). They provide scheduling flexibility while ensuring assessments are performed at appropriate intervals to maintain the scientific validity of the collected data.

SOCRA CCRP - SOCRA Certified Clinical Research Professional Practice Test

SOCRA CCRP - SOCRA Certified Clinical Research Professional Practice Test

SOCRA CCRP Study Protocols 3